These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14518756)

  • 1. Prophylactic brimonidine before LASIK.
    Uretmen O; Ates H; Andaç K
    J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis.
    Norden RA
    J Refract Surg; 2002; 18(4):468-71. PubMed ID: 12160159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early flap dislocation with perioperative brimonidine use in laser in situ keratomileusis.
    Nowroozzadeh MH
    J Cataract Refract Surg; 2010 Feb; 36(2):368. PubMed ID: 20152647
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased risk for flap dislocation with perioperative brimonidine use in femtosecond laser in situ keratomileusis.
    Muñoz G; Albarrán-Diego C; Sakla HF; Javaloy J
    J Cataract Refract Surg; 2009 Aug; 35(8):1338-42. PubMed ID: 19631117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients.
    Walter KA; Gilbert DD
    Ophthalmology; 2001 Aug; 108(8):1434-8. PubMed ID: 11470696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
    Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apraclonidine and LASIK.
    Aslanides IM; Tsiklis NS; Pallikaris IG; Jankov MR; Coskunseven E; Ozkilic E
    Ophthalmology; 2005 Dec; 112(12):2238; author reply 2244. PubMed ID: 16325717
    [No Abstract]   [Full Text] [Related]  

  • 9. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract]   [Full Text] [Related]  

  • 10. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of brimonidine before LASIK with femtosecond laser-created flaps for the correction of myopia: a contralateral eye study.
    Rodríguez-Galietero A; Martínez JV; Del Buey A; Bescós JA
    J Refract Surg; 2010 Jan; 26(1):28-32. PubMed ID: 20199009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination brimonidine and timolol.
    Kerr NM; Gross KA; Tombleson M; Danesh-Meyer HV
    Ophthalmology; 2010 Jan; 117(1):193-193.e1. PubMed ID: 20114113
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
    Walters TR
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent central nervous system depression in infants after the use of topical brimonidine.
    Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
    Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials].
    Vinuesa-Silva JM; Vinuesa-Silva I; Pinazo-Durán MD; Soto-Alvarez J; Delgado-Ortega L; Díaz-Cerezo S
    Arch Soc Esp Oftalmol; 2009 Apr; 84(4):199-207. PubMed ID: 19384760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.